We aim to deliver oral small-molecule and injectable protein therapeutics to target challenging diseases. Community guidelines: https://xitter.gq/t.co/HJsf9ax79K.
Durham, North Carolina
Joined July 2012
- Tweets369
- Following51
- Followers2.4K
- Likes16
We’re looking forward to presenting new data from our hereditary angioedema (#HAE) portfolio at the @ACAAI 2026 Annual Scientific Meeting bit.ly/47HTYwm #ACAAI26
We are excited to announce that the US FDA has approved an oral pellet formulation of our prophylactic therapy for the treatment of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. ir.biocryst.com/news-release…
Today we announced the formation of a Scientific Advisory Board comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. Learn more: ir.biocryst.com/news-release…
Join us in welcoming Ling Wang as SVP, Head of Biometrics & Data Sciences. Ling will lead the strategy and execution of clinical data and analytics across our clinical development programs, helping accelerate development and support the advancement of innovative therapies.
We're proud to announce the approval of our prophylactic therapy for the treatment of hereditary angioedema (HAE) in children aged 2 to <12 years in Japan. Learn more: bit.ly/4y5e1A6
Join us in welcoming Tong Zhu, PhD, as SVP, Head of Clinical Pharmacology, QSP & Toxicology. Dr. Zhu will help transform scientific and clinical data into informed decisions that advance our programs, strengthen development strategies, and support better outcomes for patients.
Today, we reported our Q2 2026 financial results which delivered continued revenue growth and reflect strong execution across our commercial and development priorities. Learn more about our results: bit.ly/457CcRY
We appointed David W. Jenkins, MA, PhD, as Chief Scientific Officer. Dr. Jenkins will build and lead a research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of rare disease therapies to patients. bit.ly/4ffaNSJ
We presented new clinical data and real-world evidence demonstrating the impact of our hereditary angioedema (#HAE) portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting (@EAACI_HQ): bit.ly/4vNA6C3 #EAACI2026 #HereditaryAngioedema
We will present seven abstracts from our hereditary angioedema (#HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress taking place in Istanbul, Turkey, from June 12-15. Learn more: bit.ly/4dHQFb2 @EAACI_HQ #EAACI2026
We are presenting at the 2026 @ISPORorg conference, sharing real-world evidence highlighting the significant healthcare and quality of life burden associated with hereditary angioedema (#HAE). Learn more: bit.ly/4uaFy1n #ISPORAnnual #ISPOR2026
Today, we reported our Q1 2026 financial results which reflect our continued focus on strong execution and financial discipline. Learn more about our results: bit.ly/42dJFNQ
Today we announced the appointment of Sandeep Menon, MD, PhD, as Chief Research and Development Officer. Dr. Menon joins BioCryst as an experienced R&D leader with a track record of advancing innovative therapies from early development to global approval. bit.ly/4cs3t5P
We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field in at #AAAAI26. bit.ly/4al9Eqc @AAAAI_org
We are excited to announce that John Ruesch has joined BioCryst as Chief Technical Operations Officer. bit.ly/49EGZ0h
Happening now: BioCryst is presenting at #JPM2026. Access the webcast here: (bit.ly/3C9gv96) #JPMHC26
We’re excited to come together with the healthcare industry today at the 44th Annual @jpmorgan Healthcare Conference, where we will present our latest updates and business outlook for the year. Learn more: bit.ly/3LHLNbQ #JPM2026 #JPMHC26 #JPM26
The FDA approval of our prophylactic therapy for children aged 2 to <12 with hereditary angioedema marks a transformative moment for families who live with HAE and the physicians who treat the condition. bit.ly/48KnvW9
We are proud to announce that the US FDA approved our prophylactic therapy for the treatment of hereditary angioedema (HAE) in children aged 2 to <12 years. bit.ly/48KnvW9
Today we announced the presentation of new data at the @ACAAI 2025 Annual Scientific Meeting. Stop by our poster sessions to learn more. #ACAAI25 bit.ly/3LqZQlJ
